Deciphera Pharmaceuticals, Inc.
(NASDAQ : DCPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.11%63.131.0%$460.49m
AMGNAmgen, Inc. 0.24%241.081.3%$449.61m
BIIBBiogen, Inc. -0.24%285.451.4%$388.11m
ILMNIllumina, Inc. -0.56%324.143.5%$318.73m
VRTXVertex Pharmaceuticals, Inc. -1.03%233.091.9%$297.02m
REGNRegeneron Pharmaceuticals, Inc. -0.59%383.302.6%$228.51m
EXASEXACT Sciences Corp. -0.70%89.1524.0%$202.95m
ALXNAlexion Pharmaceuticals, Inc. 1.30%113.972.0%$196.40m
ITCIIntra-Cellular Therapies, Inc. 0.68%26.819.0%$176.98m
INCYIncyte Corp. -0.12%80.522.5%$149.18m
SRPTSarepta Therapeutics, Inc. -1.77%127.9914.6%$142.57m
ARWRArrowhead Pharmaceuticals, Inc. -0.93%56.5811.4%$132.23m
SGENSeattle Genetics, Inc. 0.95%108.686.1%$126.62m
BMRNBioMarin Pharmaceutical, Inc. -0.72%88.494.3%$108.50m
AAgilent Technologies, Inc. 0.69%90.081.6%$106.45m

Company Profile

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.